Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 177,566,576
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.85
  • Price/Sales 4.47
  • Price/Cash Flow 11.22
  • Price/Book 4.45

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.10 +4.54%
on 05/01/17
65.25 -0.51%
on 05/11/17
+2.22 (+3.54%)
since 04/26/17
3-Month
61.87 +4.93%
on 04/21/17
66.80 -2.81%
on 03/01/17
-1.24 (-1.87%)
since 02/24/17
52-Week
55.10 +17.82%
on 06/27/16
66.80 -2.81%
on 03/01/17
+8.53 (+15.13%)
since 05/26/16

Most Recent Stories

More News
Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others

Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others

ABT : 44.71 (+1.73%)
V : 94.67 (-0.39%)
MS : 42.84 (+0.49%)
MRK : 64.92 (-0.18%)
GSK : 42.67 (+0.23%)
GE : 27.45 (-0.15%)
UnitedHealth's (UNH) Business Unit Collaborates with Merck

UnitedHealth Group, Inc.???s (UNH) information and technology-enabled health services business "Optum" recently announced its collaboration with Merck & Co. Inc (MRK).

HUM : 232.25 (+0.01%)
MRK : 64.92 (-0.18%)
WCG : 172.97 (+0.09%)
INGN : 87.93 (-1.15%)
UNH : 177.50 (-0.31%)
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody....

MRK : 64.92 (-0.18%)
UNH : 177.50 (-0.31%)
BMY : 53.97 (-0.77%)
BIIB : 250.80 (-0.86%)
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
AMGN : 155.01 (-0.27%)
PFE : 32.14 (-0.06%)
Celldex's Immuno-Oncology Pipeline Continues to Impress

On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

CLDX : 3.06 (-1.29%)
MRK : 64.92 (-0.18%)
PFE : 32.14 (-0.06%)
BMY : 53.97 (-0.77%)
The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana

The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana

HUM : 232.25 (+0.01%)
F : 10.93 (+0.64%)
MRK : 64.92 (-0.18%)
UTX : 121.85 (-0.33%)
MMM : 200.67 (+0.57%)
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

AERI : 55.90 (+3.04%)
MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
GWPH : 106.13 (-1.75%)
PFE : 32.14 (-0.06%)
SNY : 49.00 (-0.06%)
BMY : 53.97 (-0.77%)
New Stock Research Reports for Merck, 3M and United Technologies

New Stock Research Reports for Merck, 3M and United Technologies

HUM : 232.25 (+0.01%)
SHW : 334.95 (+0.26%)
F : 10.93 (+0.64%)
MRK : 64.92 (-0.18%)
UTX : 121.85 (-0.33%)
MMM : 200.67 (+0.57%)
Optum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals

Optum, the health services business of UnitedHealth Group (NYSE: UNH), and Merck (NYSE: MRK, known as MSD outside the U.S. and Canada), will collaborate to develop and simulate the performance...

MRK : 64.92 (-0.18%)
UNH : 177.50 (-0.31%)
Indigenous Researchers Receive $2.6 Million Funding From Merck Canada Inc. for Indigenous Maternal and Child Health Program in Ontario

A unique Indigenous-led, community-hospital-university-private sector partnership to enhance Indigenous maternal and child health will address some of the underlying causes of health inequity through an...

MRK : 64.92 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 65.37
1st Resistance Point 65.15
Last Price 64.92
1st Support Level 64.76
2nd Support Level 64.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.